Clinicopathological Features of Young Gastric Cancer and New Inflammatory Prognostic Markers
Yıl: 2023 Cilt: 56 Sayı: 2 Sayfa Aralığı: 90 - 96 Metin Dili: İngilizce DOI: 10.5505/aot.2023.74317 İndeks Tarihi: 09-12-2023
Clinicopathological Features of Young Gastric Cancer and New Inflammatory Prognostic Markers
Öz: INTRODUCTION: This study aimed to evaluate the clinicopathologic features of young gastric cancer (GC) patients and to investigate the factors affecting survival (OS). METHODS: In this study, the data of 55 patients diagnosed under the age of 40 were obtained by retrospective evaluation of hospital records. Clinicopathological features and some laboratory parameters of this patient group and new inflammatory prognostic markers (IPM) obtained from these parameters were evaluated. RESULTS: The mean age of the patients in this study was 33 years. The majority of the patients were male. Patients were evaluated according to human C-erbB2 positivity too. The identified patients as positive were only 7% of all patients. Also, the patients were evaluated for platinum sensitivity too. It was found that 30% of the patients were sensitive to platinum treatments. Also, survival times of the patients were evaluated with IPM. Neutrophil-lymphocyte ratio (NLR), mean platelet volume/platelet count, C-reactive protein/albumin ratios were calculated separately. Survival results were analyzed based on the mean values of all 3 prognostic markers. Even though there was a significant numerical difference, no statistical significance was found. DISCUSSION AND CONCLUSION: This study was conducted to examine the clinicopathological features and survival time of young GC patients. Low C-erbB2 positivity and high platinum resistance were found among this patient population. In addition, inflammatory prognostic markers, which were found to be associated with survival in most cancers, were found to cause significant numerical differences in terms of survival in our study.
Anahtar Kelime: Genç Mide Kanserinin Klinikopatolojik Özellikleri ve Yeni İnflamatuar Prognostik Belirteçler
Öz: Giriş: Bu çalışma genç mide kanseri (GC) hastalarının clinicopathologic özelliklerini değerlendirmek ve sağ kalıma (OS) etki eden faktörleri araştırmayı amaçladı. Gereç ve yöntemler: Bu çalışmada, hastane kayıtlarının retrospektif olarak değerlendirilmesi ile 40 yaş altı tanı almış 55 hastanın verileri elde edilmiştir. Bu hasta grubunun klinikopatolojik özellikleri ve bazı laboratuvar parametreleri ile bu parametrelerden elde edilen yeni inflamatuar prognostik belirteçler (IPM) değerlendirildi. Bulgular: Çalışmamızda hastaların ortalama yaşı 33’tü. Erkek hastaların sayısı çoğunluktaydı. Hastalar C-erbB2 pozitifliğine göre de değerlendirildi. Pozitif olarak saptanan hastalar, tüm hastaların sadece %7’siydi. Hastalar aynı zamanda platin duyarlılığı açısından da değerlendirildi. Hastaların %30’unun platin tedavilerine karşı duyarlı olarak saptandı. Hastaların SK süreleri inflamatuar prognostik belirteçler eşliğinde de değerlendirildi. Nötrofil-lenfosit oranı (NLR), ortalama platelet volümü/platelet sayısı (MPV/platelet sayısı), C-reaktif protein/albümin oranları (CAR) ayrı ayrı hesaplandı. Her 3 prognostik belirtecin de ortalama değerleri baz alınarak SK sonuçları incelendi. Bu değerler ve SK arasında rakamsal olarak belirgin farklılık olmasına rağmen istatistiksel bir anlamlılık saptanmadı. Tartışma: Bu çalışma genç mide kanseri hastalarının klinikopatolojik özelliklerini ve SK sürelerini incelemek için yapılmıştır. Çalışmamız sonucunda bu hasta grubunda düşük C-erbB2 pozitiflik oranı ve yüksek platin direnci olduğu saptanmıştır. Ayrıca çoğu kanserde sağkalımla ilişkili olduğu saptanan inflamatuar prognostik belirteçlerin, çalışmamızda da SK açısından belirgin rakamsal farklılık oluşturduğu görülmüştür.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018; 68(6): 394-424.
- 2. De B, Rhome R, Jairam V, et al. Gastric adenocarcinoma in young adult patients: patterns of care and survival in the United States. Gastric Cancer. 2018; 21(6): 889-899.
- 3. Geiger AM, Castellino SM. Delineating the age ranges used to define adolescents and young adults. Journal of Clinical Oncology. 2011; 29(16): 2010-2011.
- 4. Al-Refaie WB, Hu CY, Pisters PWT, Chang GJ. Gastric adenocarcinoma in young patients: A population-based appraisal. Annals of Surgical Oncology. 2011; 18(10): 2800-2807.
- 5. Smith AW, Bellizzi KM, Keegan THM, et al. Health-related quality of life of adolescent and young adult patients with cancer in the United States: The adolescent and young adult health outcomes and patient experience study. Journal of Clinical Oncology. 2013; 31(17): 2136-2145.
- 6. Lochhead P, El-Omar EM. Gastric cancer. British Medical Bulletin. 2008; 85(1): 87-100.
- 7. Washington K. 7th edition of the AJCC cancer staging manual: Stomach. Annals of Surgical Oncology. 2010; 17(12): 3077- 3079.
- 8. Anderson WF, Camargo MC, Fraumeni JF, Correa P, Rosenberg PS, Rabkin CS. Age-specific trends in incidence of noncardia gastric cancer in US adults. JAMA - Journal of the American Medical Association. 2010; 303(17): 1723-1728.
- 9. Leung WK, Wu MS, Kakugawa Y, et al. Screening for Gastric Cancer in Asia: Current Evidence and Practice.; 2008. http://oncology. thelancet.com
- 10. Ramos MFKP, Pereira MA, Sagae VMT, et al. Gastric cancer in young adults: A worse prognosis group? Revista do Colegio Brasileiro de Cirurgioes. 2019; 46(4): e20192256..
- 11. Takatsu Y, Hiki N, Nunobe S, et al. Clinicopathological features of gastric cancer in young patients. Gastric Cancer. 2016; 19(2): 472-478.
- 12. Li J. Gastric Cancer in Young Adults: A Different Clinical Entity from Carcinogenesis to Prognosis. Gastroenterology Research and Practice. 2020; ID: 9512707.
- 13. Korea S, Bang YJ, Bang YJ, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. The Lancet. 2010; 376: 687-697.
- 14. Takashima T, Taniyama D, Sakamoto N, et al. Schlafen 11 predicts response to platinum-based chemotherapy in gastric cancers. British Journal of Cancer. 2021; 125(1): 65-77.
- 15. Wang Z, Chen JQ, Liu JL, Qin XG, Huang Y. Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: A systematic review. BMC Gastroenterology. 2012; 12, 137.
- 16. Chang L, BChir M, Chang M, Chang HM, Chang F. Microsatellite Instability: A Predictive Biomarker for Cancer Immunotherapy.; 2017. www.appliedimmunohist.com
- 17. Cristescu R, Lee J, Nebozhyn M, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nature Medicine. 2015; 21(5): 449-456.
- 18. Toyokawa T, Muguruma K, Yoshii M, et al. Clinical significance of prognostic inflammation-based and/or nutritional markers in patients with stage III gastric cancer. BMC Cancer. 2020; 20, 517.
- 19. Kim MR, Kim AS, Choi HI, Jung JH, Park JY, Ko HJ. Inflammatory markers for predicting overall survival in gastric cancer patients: A systematic review and meta-analysis. PLoS ONE. 2020; 15(7), e: 0236445.
| APA | gülmez a, DİKİLİTAŞ M (2023). Clinicopathological Features of Young Gastric Cancer and New Inflammatory Prognostic Markers. , 90 - 96. 10.5505/aot.2023.74317 |
| Chicago | gülmez ahmet,DİKİLİTAŞ MUSTAFA Clinicopathological Features of Young Gastric Cancer and New Inflammatory Prognostic Markers. (2023): 90 - 96. 10.5505/aot.2023.74317 |
| MLA | gülmez ahmet,DİKİLİTAŞ MUSTAFA Clinicopathological Features of Young Gastric Cancer and New Inflammatory Prognostic Markers. , 2023, ss.90 - 96. 10.5505/aot.2023.74317 |
| AMA | gülmez a,DİKİLİTAŞ M Clinicopathological Features of Young Gastric Cancer and New Inflammatory Prognostic Markers. . 2023; 90 - 96. 10.5505/aot.2023.74317 |
| Vancouver | gülmez a,DİKİLİTAŞ M Clinicopathological Features of Young Gastric Cancer and New Inflammatory Prognostic Markers. . 2023; 90 - 96. 10.5505/aot.2023.74317 |
| IEEE | gülmez a,DİKİLİTAŞ M "Clinicopathological Features of Young Gastric Cancer and New Inflammatory Prognostic Markers." , ss.90 - 96, 2023. 10.5505/aot.2023.74317 |
| ISNAD | gülmez, ahmet - DİKİLİTAŞ, MUSTAFA. "Clinicopathological Features of Young Gastric Cancer and New Inflammatory Prognostic Markers". (2023), 90-96. https://doi.org/10.5505/aot.2023.74317 |
| APA | gülmez a, DİKİLİTAŞ M (2023). Clinicopathological Features of Young Gastric Cancer and New Inflammatory Prognostic Markers. ACTA ONCOLOGICA TURCICA, 56(2), 90 - 96. 10.5505/aot.2023.74317 |
| Chicago | gülmez ahmet,DİKİLİTAŞ MUSTAFA Clinicopathological Features of Young Gastric Cancer and New Inflammatory Prognostic Markers. ACTA ONCOLOGICA TURCICA 56, no.2 (2023): 90 - 96. 10.5505/aot.2023.74317 |
| MLA | gülmez ahmet,DİKİLİTAŞ MUSTAFA Clinicopathological Features of Young Gastric Cancer and New Inflammatory Prognostic Markers. ACTA ONCOLOGICA TURCICA, vol.56, no.2, 2023, ss.90 - 96. 10.5505/aot.2023.74317 |
| AMA | gülmez a,DİKİLİTAŞ M Clinicopathological Features of Young Gastric Cancer and New Inflammatory Prognostic Markers. ACTA ONCOLOGICA TURCICA. 2023; 56(2): 90 - 96. 10.5505/aot.2023.74317 |
| Vancouver | gülmez a,DİKİLİTAŞ M Clinicopathological Features of Young Gastric Cancer and New Inflammatory Prognostic Markers. ACTA ONCOLOGICA TURCICA. 2023; 56(2): 90 - 96. 10.5505/aot.2023.74317 |
| IEEE | gülmez a,DİKİLİTAŞ M "Clinicopathological Features of Young Gastric Cancer and New Inflammatory Prognostic Markers." ACTA ONCOLOGICA TURCICA, 56, ss.90 - 96, 2023. 10.5505/aot.2023.74317 |
| ISNAD | gülmez, ahmet - DİKİLİTAŞ, MUSTAFA. "Clinicopathological Features of Young Gastric Cancer and New Inflammatory Prognostic Markers". ACTA ONCOLOGICA TURCICA 56/2 (2023), 90-96. https://doi.org/10.5505/aot.2023.74317 |
